Nintx - Next Innovative Therapeutics

ABOUT

Nintx (Next Innovative Therapeutics) originated in Brazil as a startup with innovation as core business, heavily based on advanced technologies to develop the next generation of therapies.

Nintx relies on intra and interspecies biology (Plants/Microorganisms). The derived natural products/metabolites from these organisms and interactions thereof can lead into novel therapies for human use through the application of advanced analytical and screening techniques, metagenomics and metabolomics, computational methodologies, and medicinal chemistry. Nintx is agile, open, collaborative, technology driven and nature inspired, following ESG guiding principles, to bring future treatments today.

Nintx was founded by two PhD scientists, Dr. Miller Freitas and Dr. Cristiano Guimarães. In addition to the proven academic track record, they held prominent leadership R&D positions at the forefront of innovation in the pharmaceutical industry, both in Brazil and the US, leading innovative programs that are currently under global development. Their combined scientific knowledge and experience are crucial for both the discovery and development stages, as well as the registration of novel therapies.

OUR APPROACH

FOUNDERS

MILLER FREITAS, PhD

Founder & CEO
miller.freitas@nintx.com.br

Read more +

CRISTIANO GUIMARÃES, PhD

Founder & CSO
cristiano.guimaraes@nintx.com.br

Read more +

NEWS

CONTACTS

miller.freitas@nintx.com.br
cristiano.guimaraes@nintx.com.br